model,flat_path,key_cat,val_cat,ref_val,pred_val,val_match,sim,score_status,piece,norm_path,from_pred,in_ref,in_pred,type_mismatch,is_enum,sim_failed
Gemini-3-Pro,protocolSection.identificationModule.nctId,TP,TP,NCT04084392,NCT04084392,True,1.0,exact,NCTId,protocolSection.identificationModule.nctId,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.identificationModule.secondaryIdInfos[0].id,EV,EV,,UL1 TR002243,,,,SecondaryId,protocolSection.identificationModule.secondaryIdInfos.id,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.identificationModule.secondaryIdInfos[0].type,EV,EV,,NIH,,,,SecondaryIdType,protocolSection.identificationModule.secondaryIdInfos.type,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.identificationModule.secondaryIdInfos[0].domain,EV,EV,,National Center for Advancing Translational Sciences,,,,SecondaryIdDomain,protocolSection.identificationModule.secondaryIdInfos.domain,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.identificationModule.briefTitle,TP,TP,Evaluating the Impact of the Bridge Clinic in Patients With Opioid Use Disorder,Bridging Recovery Initiative Despite Gaps in Entry (BRIDGE),True,0.86,success,BriefTitle,protocolSection.identificationModule.briefTitle,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.identificationModule.officialTitle,TP,TP,Evaluating the Impact of the Bridge Clinic in Patients With Opioid Use Disorder,Bridging Recovery Initiative Despite Gaps in Entry (BRIDGE) trial,True,0.82,success,OfficialTitle,protocolSection.identificationModule.officialTitle,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.identificationModule.acronym,EV,EV,,BRIDGE,,,,Acronym,protocolSection.identificationModule.acronym,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.descriptionModule.briefSummary,TP,TP,This study aims to determine whether referral to the Bridge Clinic reduces overall index hospital length of stay when compared to direct referral to a long-term outpatient addiction provider for patients with active opioid use disorder (OUD) being considered for medications-for-addiction treatment (MAT).,"The Bridging Recovery Initiative Despite Gaps in Entry (BRIDGE) trial is a pragmatic, single-center, randomized controlled trial designed to evaluate the effectiveness of a transitional 'bridge' clinic for hospitalized patients with opioid use disorder (OUD). The study compares outcomes between patients referred to a co-located, multidisciplinary bridge clinic and those receiving usual care (referral to community providers). The primary objective is to determine if the bridge clinic model reduces hospital length of stay, while secondary objectives include assessing readmission rates, linkage to care, and quality of life.",True,0.92,success,BriefSummary,protocolSection.descriptionModule.briefSummary,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.descriptionModule.detailedDescription,EV,EV,,"This study is a pragmatic, superiority, randomized controlled trial enrolling hospitalized patients aged 18 and older with active opioid use disorder (OUD) who are initiating medication for OUD (MOUD), such as buprenorphine-naloxone or naltrexone, in consultation with an addiction consult service. 

Patients are randomized 1:1 to either referral to a transitional, multidisciplinary bridge clinic or to usual care. The randomization process is leveraged by the fixed capacity of the bridge clinic. The intervention group receives wraparound services from a team comprising physicians (addiction psychiatry, internal medicine, infectious diseases, pain-anesthesia), nurse practitioners, social workers, case managers, and recovery coaches. This team facilitates the transition from the hospital to long-term outpatient care. The control group receives usual care, which involves standard discharge planning and referral to community MOUD providers by the primary medical team's social worker.

The primary endpoint is the index hospital length of stay (LOS). Secondary endpoints include 16-week follow-up measures such as linkage to MOUD providers, self-reported medication fills, readmission rates, emergency department visits, recurrent opioid use, overdose, mortality, costs of care, and quality of life measurements (Schwartz Outcome Scale-10 and EQ-5D-5L). For patients with infections suitable for outpatient management, additional outcomes include recurrent infection and completion of antibiotic therapy.",,,,DetailedDescription,protocolSection.descriptionModule.detailedDescription,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.conditionsModule.conditions,TP,FP,"['Opioid Use', 'Opioid-use Disorder']","['Opioid Use Disorder', 'Substance Use Disorders', 'Injection Drug Use Related Infections']",False,0.0,disjoint,Condition,protocolSection.conditionsModule.conditions,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.conditionsModule.keywords,EV,EV,,"['Opioid Use Disorder', 'MOUD', 'Bridge Clinic', 'Transitional Care', 'Addiction Consult Service', 'Buprenorphine', 'Naltrexone', 'Hospital Medicine']",,,,Keyword,protocolSection.conditionsModule.keywords,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.designModule.studyType,TP,TP,INTERVENTIONAL,INTERVENTIONAL,True,1.0,exact,StudyType,protocolSection.designModule.studyType,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.designModule.patientRegistry,EV,EV,,False,,,,PatientRegistry,protocolSection.designModule.patientRegistry,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.designModule.phases,TP,TP,['NA'],['NA'],True,1.0,exact,Phase,protocolSection.designModule.phases,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.designModule.designInfo.allocation,TP,TP,RANDOMIZED,RANDOMIZED,True,1.0,exact,DesignAllocation,protocolSection.designModule.designInfo.allocation,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.designModule.designInfo.interventionModel,TP,TP,PARALLEL,PARALLEL,True,1.0,exact,DesignInterventionModel,protocolSection.designModule.designInfo.interventionModel,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.designModule.designInfo.maskingInfo.masking,TP,FP,SINGLE,NONE,False,0.2,success,DesignMasking,protocolSection.designModule.designInfo.maskingInfo.masking,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.designModule.designInfo.maskingInfo.maskingDescription,EV,EV,,"Given that all providers are aware of the trial itself and the randomization status of a given patient, it is possible that unconscious or conscious biases will lead to differential treatment of patients based on randomization condition.",,,,DesignMaskingDescription,protocolSection.designModule.designInfo.maskingInfo.maskingDescription,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.designModule.designInfo.maskingInfo.whoMasked,FN,FN,['OUTCOMES_ASSESSOR'],,False,0.0,,DesignWhoMasked,protocolSection.designModule.designInfo.maskingInfo.whoMasked,False,True,False,False,False,False
Gemini-3-Pro,protocolSection.designModule.enrollmentInfo.count,TP,TP,335,336,True,0.99,success,EnrollmentCount,protocolSection.designModule.enrollmentInfo.count,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[0].measure,EV,EV,,"New, persistent, or recurrent infection",,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[1].measure,EV,EV,,Completion of antibiotic therapy,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[2].measure,EV,EV,,Days from negative blood culture to discharge,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[3].measure,EV,EV,,Acceptance of referral,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[4].measure,EV,EV,,Cross-over rates,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[5].measure,EV,EV,,Reasons for ineligibility,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[0].description,EV,EV,,Defined by a positive culture and/or change in antibiotic regimen (for patients with infection suitable for outpatient management).,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[1].description,EV,EV,,Assessment of antibiotic therapy completion (for patients with infection suitable for outpatient management).,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[2].description,EV,EV,,The number of days from negative blood culture to first hospital discharge (for patients with infection suitable for outpatient management).,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[3].description,EV,EV,,Implementation measurement regarding acceptance of referral to bridge clinic.,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[4].description,EV,EV,,Cross-over from usual care to bridge clinic and vice versa.,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[5].description,EV,EV,,Documented reasons why patients were not eligible for referral.,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[0].timeFrame,EV,EV,,16-week follow-up period,,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[1].timeFrame,EV,EV,,16-week follow-up period,,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[2].timeFrame,EV,EV,,Index hospital admission,,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[3].timeFrame,EV,EV,,During hospital admission,,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[4].timeFrame,EV,EV,,16-week follow-up period,,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.outcomesModule.otherOutcomes[5].timeFrame,EV,EV,,Baseline,,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Gemini-3-Pro,protocolSection.eligibilityModule.eligibilityCriteria,TP,TP,"Inclusion Criteria:

* Inpatients at VUH with active OUD being considered for MAT.
* Patient accepting a transitional prescription for buprenorphine-naloxone or IM naltrexone whose outpatient plans are not fixed

Exclusion Criteria:

* Deemed ineligible for referral to outpatient Bridge Clinic by the Addiction Consult Team (examples include but are not limited to patients with severe, active co-occurring psychiatric disorders requiring a higher level of psychiatric care or patients for whom methadone maintenance is deemed the best choice of MAT).
* Patients previously randomized in this study.","Inclusion criteria:
* Aged â‰¥ 18 years
* Active OUD being considered for MOUD evidenced by accepting a transitional prescription for buprenorphine-naloxone or intramuscular naltrexone injection
* Outpatient plans not fixed prior to admission, defined as a patient reporting a prior relationship with an MOUD provider that they intend to continue after discharge, including cash pay practices
* Patient lives in one of the counties that comprise Middle Tennessee, shown in an additional file listing appropriate zip codes (see Additional file2), in order to ensure a reasonable chance of the patient having regular transportation to the clinic

Exclusion criteria:
* Severe, active co-occurring psychiatric disorders that require a higher level of psychiatric care
* Patients for whom methadone maintenance is deemed the best choice of MOUD
* Patients previously randomized in this study
* Patients who previously were referred to the bridge clinic prior to study initiation",True,0.9,success,EligibilityCriteria,protocolSection.eligibilityModule.eligibilityCriteria,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.eligibilityModule.healthyVolunteers,TP,TP,False,False,True,1.0,exact,HealthyVolunteers,protocolSection.eligibilityModule.healthyVolunteers,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.eligibilityModule.sex,TP,TP,ALL,ALL,True,1.0,exact,Sex,protocolSection.eligibilityModule.sex,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.eligibilityModule.minimumAge,TP,TP,18 Years,18 Years,True,1.0,exact,MinimumAge,protocolSection.eligibilityModule.minimumAge,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.eligibilityModule.maximumAge,EV,EV,,N/A,,,,MaximumAge,protocolSection.eligibilityModule.maximumAge,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.eligibilityModule.stdAges,TP,TP,"['ADULT', 'OLDER_ADULT']","['ADULT', 'OLDER_ADULT']",True,1.0,exact,StdAge,protocolSection.eligibilityModule.stdAges,False,True,True,False,True,False
